{
    "Trade/Device Name(s)": [
        "Calcium2"
    ],
    "Submitter Information": "Abbott Ireland Diagnostics Division",
    "510(k) Number": "K244042",
    "Predicate Device Reference 510(k) Number(s)": [
        "K062855"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CJY"
    ],
    "Summary Letter Date": "February 10, 2025",
    "Summary Letter Received Date": "December 30, 2024",
    "Submission Date": "December 30, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1145"
    ],
    "Regulation Name(s)": [
        "Calcium test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Calcium"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine"
    ],
    "Specimen Container(s)": [
        "Serum tube",
        "Serum separator tube",
        "Lithium heparin tube",
        "Lithium heparin separator tube",
        "Sodium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT c System",
        "ARCHITECT c8000 System"
    ],
    "Method(s)/Technology(ies)": [
        "Arsenazo III dye colorimetric assay"
    ],
    "Methodologies": [
        "Automated clinical chemistry assay",
        "Colorimetric measurement at 660 nm"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Calcium2 colorimetric clinical chemistry assay for quantitative determination of calcium in serum, plasma, or urine on the ARCHITECT c System.",
    "Indications for Use Summary": "Quantitative determination of calcium in human serum, plasma, or urine on the ARCHITECT c System, aiding diagnosis and treatment of parathyroid disease, bone diseases, chronic renal disease, and tetany.",
    "fda_folder": "Clinical Chemistry"
}